[June 24, 2016] |
|
Global Myelodysplastic Syndrome Pipeline Report 2016 - Pipeline Review of 92 Therapeutic Companies - Research and Markets
Research and Markets has announced the addition of the "Myelodysplastic
Syndrome - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic
development for Myelodysplastic Syndrome, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Myelodysplastic Syndrome and special features on late-stage and
discontinued projects.
The report enhances decision-making capabilities and helps to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Key Topics Covered:
-
Introduction
-
Myelodysplastic Syndrome Overview
-
Therapeutics Development
-
Pipeline Products for Myelodysplastic Syndrome - Overview
-
Pipeline Products for Myelodysplastic Syndrome - Comarative Analysis
-
Myelodysplastic Syndrome - Therapeutics under Development by Companies
-
Myelodysplastic Syndrome - Therapeutics under Investigation by
Universities/Institutes
-
Myelodysplastic Syndrome Products Glance
-
Late Stage Products
-
Clinical Stage Products
-
Early Stage Products
-
Myelodysplastic Syndrome - Products under Development by Companies
-
Myelodysplastic Syndrome - Products under Investigation by
Universities/Institutes
-
Myelodysplastic Syndrome - Companies Involved in Therapeutics
Development
-
4SC AG
-
Acceleron Pharma, Inc.
-
Actinium Pharmaceuticals, Inc.
-
Aeglea BioTherapeutics, Inc.
-
Agios Pharmaceuticals, Inc.
-
Altor BioScience Corporation
-
Amgen Inc.
-
Apogenix GmbH
-
Arno Therapeutics, Inc.
-
Arog Pharmaceuticals, Inc.
-
Array BioPharma Inc.
-
Astex Pharmaceuticals, Inc.
-
Atara Biotherapeutics, Inc.
-
Bellicum Pharmaceuticals, Inc.
-
Bio-Path Holdings, Inc.
-
BioLineRx, Ltd.
-
BioLite, Inc.
-
Boehringer Ingelheim GmbH
-
Boryung Pharmaceutical Co., Ltd.
-
Boston Biomedical, Inc.
-
Bristol-Myers Squibb Company
-
Cantex Pharmaceuticals, Inc.
-
Celator Pharmaceuticals, Inc.
-
Celgene Corporation
-
Celldex Therapeutics, Inc.
-
Cellerant Therapeutics, Inc.
-
Celyad SA
-
Constellation Pharmaceuticals, Inc.
-
Cornerstone Pharmaceuticals, Inc.
-
CrystalGenomics, Inc.
-
CTI (News - Alert) BioPharma Corp.
-
Cyclacel Pharmaceuticals, Inc.
-
Daiichi Sankyo Company, Limited
-
DiNonA Inc.
-
Eisai Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/tqcm9f/myelodysplastic
View source version on businesswire.com: http://www.businesswire.com/news/home/20160624005246/en/
[ Back To TMCnet.com's Homepage ]
|